Takeda Says Samsung Biosimilar Plans Infringe Entyvio IP
Takeda has fought back against Samsung's bid to nix two patents covering its Entyvio-branded drug for Crohn's disease, arguing that the rival was infringing its rights with plans to commercialize biosimilar...To view the full article, register now.
Already a subscriber? Click here to view full article